Storia in 2 fonti

Attovia extends biotech IPO streak with $289M listing for three I&I drugs

Attovia Therapeutics (ATTO) raises upsized IPO on Nasdaq, extending biotech's 3-week streak. CEO Tao Fu's firm targets I&I with drugs ATTO-1310, ATTO-2306, ATTO-1091.

Raccontata da

biopharmadive.com

endpoints.news

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo3 g fa

Attovia extends biotech IPO streak with $289M listing for three I&I drugs

Attovia Therapeutics (ATTO) raises upsized IPO on Nasdaq, extending biotech's 3-week streak. CEO Tao Fu's firm targets I&I with drugs ATTO-1310, ATTO-2306, ATTO-1091.

originale

biopharmadive.com3 g fa

Attovia adds to biotech IPO momentum with $289M offering

The startup is the 12th drug company to bank at least $250 million in an IPO this year, nearly matching totals last seen during the sector’s pandemic peak, according to BioPharma Dive data.

Leggi questa versione → originale

Timeline cronologica

mercoledì 5 agosto 2026·biopharmadive.com
Attovia adds to biotech IPO momentum with $289M offering
The startup is the 12th drug company to bank at least $250 million in an IPO this year, nearly matching totals last seen during the sector’s pandemic peak, according to BioPharma…
mercoledì 5 agosto 2026·endpoints.news
Attovia extends biotech IPO streak with $289M listing for three I&I drugs
Attovia Therapeutics (ATTO) raises upsized IPO on Nasdaq, extending biotech's 3-week streak. CEO Tao Fu's firm targets I&I with drugs ATTO-1310, ATTO-2306, ATTO-1091.